- Last week, Inventiva (NASDAQ:IVA) announced a licensing and collaboration agreement with Sino Biopharm’s subsidiary Chia Tai-Tianqing Pharmaceutical Group (CTTQ) to develop and commercialize lanifibranor in Greater China.
- Regardless of CTTQ’s decision on lanifibranor’s clinical development pathway in China, HC Wainwright notes that Sino Biopharm is a vertically-integrated company with substantial R&D, manufacturing, sales, and marketing capability.
- The analyst regards the collaboration as a financially prudent pathway for lanifibranor’s expansion to a major NASH market, given Sino Biopharm’s experience as a commercial-stage company in Greater China.
- HC Wainwright affirms a Buy rating but lowered the price target from $42 to $36 based on the expected enrollment delay for the pivotal Phase 3 NATiV3 trial.
- The analyst adjusted the projected sales trajectory of lanifibranor for the treatment of NASH to reflect the latest clinical timeline (last patient’s first visit in 2H23, and top-line data readout in 2H25).
- These changes reduced the analyst’s projected peak revenues of lanifibranor in NASH to €1.7 billion in 2034 (previously €1.9 billion).
- Price Action: IVA shares are up 0.26% at $3.93 on the last check Monday.
Elastic Announces AI Assistant For Observability And General Availability Of Universal Profiling
Transforms observability by empowering site reliability engineers with unified and limitless visibility into complex cloud-native environmentsElastic® (NYSE:ESTC) ("Elastic"), the company behind Elasticsearch®,
